Bay Colony Advisors’s Lifecore Biomedical LFCR Stock Holding History

Bay Colony Advisors’s Portfolio LFCR Stock Details LFCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-17	Closed	–	–	594
2018 Q2	$0	Buy	+17	New	+$236	﹤0.01%	953

Other funds holding LFCR

NIMC

NWQ Investment Management Company Los Angeles, California $2.22B AUM 6.84% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Wynnefield Capital New York $148M AUM 32.71% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return

Walthausen & Co Malta, New York $120M AUM 2.66% 1-Year Est. Return

ICOM

Investment Counselors of Maryland Baltimore, Maryland $4.37B AUM 76.25% 1-Year Est. Return

Bay Colony Advisors's LFCR Position: Q3 2018 in Review

Bay Colony Advisors sold out of Lifecore Biomedical (LFCR) in Q3 2018, closing a stake of 17 shares.

Bay Colony Advisors first reported a position in LFCR in Q2 2018 and held it in 1 quarter. The position peaked at $0 in Q2 2018. 90 funds tracked by Wall St. Rank hold LFCR as of Q3 2018.

Bay Colony Advisors reported no remaining Lifecore Biomedical position as of Q3 2018 after selling out during the quarter.
Bay Colony Advisors sold 17 Lifecore Biomedical shares in Q3 2018.
Bay Colony Advisors first reported a position in Lifecore Biomedical in Q2 2018 and held it in 1 quarter.
Bay Colony Advisors's Lifecore Biomedical position peaked at $0 in Q2 2018.
90 funds tracked by Wall St. Rank held Lifecore Biomedical as of Q3 2018.

Based on Bay Colony Advisors's 13F filing for Q3 2018, filed 5 Nov 2018.